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1. Abstract 
There is a critical need for blood pressure lowering strategies that have 
greater efficacy and minimal side effects. Low-dose combinations hold 
promise in this regard, but there are few data on very low dose therapy.  
We therefore conducted a systematic review and meta-analysis of 
randomised controlled trials with at least one quarter-dose and one placebo 
and/or standard dose monotherapy arm. A search was conducted of Medline, 
Embase, Cochrane Registry, Food and Drug Administration and European 
Medicinal Agency websites. Data on blood pressure and adverse events were 
pooled using a fixed-effect model and bias was assessed using Cochrane risk 
of bias. 
The review included 42 trials involving 20,284 participants. Thirty six 
comparisons evaluated quarter-dose with placebo and indicated a blood 
pressure reduction of -4.7/ -2.4 mmHg (p<0.001). Six comparisons were of 
dual quarter-dose therapy vs. placebo, observing a -6.7/ -4.4 mmHg (p<0.001) 
blood pressure reduction. There were no trials of triple quarter-dose 
combination vs. placebo but one quadruple quarter-dose study observed a 
blood pressure reduction of -22.4/ -13.1 mmHg vs. placebo (p<0.001).  
Compared to standard dose monotherapy, the blood pressure differences 
achieved by single (37 comparisons), dual (7 comparisons) and quadruple (1 
trial) quarter dose combinations were +3.7/+2.6 (p<0.001), +1.3/-0.3 (NS) and 
-13.1/-7.9 (p<0.001) mmHg respectively. In terms of adverse events, single 
and dual quarter-dose therapy was not significantly different from placebo and 
had significantly fewer adverse events compared to standard dose 
monotherapy.  
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Quarter dose combinations could provide improvements in efficacy and 
tolerability of blood pressure lowering therapy. 
 
Keywords: Blood pressure lowering, combination therapy, quarter dose, meta-
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INTRODUCTION 
High blood pressure is the leading cause of preventable morbidity and 
mortality globally.1 Yet control of blood pressure is poor, with only 1 in 3 
people on treatment achieving blood pressure targets.2-5 The largest global 
survey of hypertension practice showed that while 88% of those aware of 
hypertension receive some pharmacological treatment, only 34% of those 
treated were controlled. Overall, 61% of those treated only received 
monotherapy5 even though combination therapy is usually required to achieve 
acceptable levels of blood pressure control.6 In the absence of more effective 
new blood pressure drug classes, better blood pressure control is likely to 
require more use of existing agents in combination.  
 
Minimization of side effects is critical for long-term treatment of a largely 
asymptomatic condition such as high blood pressure. Several studies suggest 
low-dose combinations may provide the best ratio of side effects to blood 
pressure reduction, since at low doses most side effects are avoided and 
most benefit is realised.7 Given that blood pressure dose response gradients 
are typically shallow above quarter standard dose,7 combinations containing 
quarter doses of several antihypertensive agents may be of particular benefit. 
One small trial reported in 2007 a very large blood pressure reduction from 
quadruple quarter dose combination therapy compared to monotherapy8 and 
a small trial recently completed also showed large reductions compared to 
placebo.9 We therefore conducted a systematic review of randomised trials of 
quarter-dose blood pressure lowering agent(s) to place these trials in the 
context of all evidence concerning quarter dose therapy, and to assess the 
potential clinical role of quarter dose monotherapy and combination therapy.  
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METHODS 
The review methods are detailed in the protocol (supplementary file 1) and 
were written in accordance with the preferred Cochrane Collaboration 
reporting items for systematic reviews and meta-analyses. 
Search strategy and selection criteria 
Electronic searches were conducted in EMBASE (inception - June 2016), 
MEDLINE (inception - June 2016), Cochrane Central Registry of Controlled 
Trials (CCRCT/CENTRAL) (inception - June 2016) and the Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) websites. 
Searches of trial registers were performed for any ongoing trials including 
World Health Organization International Clinical Trials Registry Platform 
(WHO-ICTRP), Australia New Zealand Clinical Trial Register (ANZCTR) and 
Clinical Trials Registry – India (CTRI). Retrieval of studies from reference lists 
of key clinical trials, systematic reviews and published articles was also 
undertaken. The Medline search has been included in the supplementary 
material (please see http://hyper.ahajournals.org). 
During the initial phase of the search, two reviewers (AB, MC) independently 
performed the searches assessing titles and abstracts, excluding any studies 
that did not qualify. Both the reviewers then inspected the full text of those 
selected articles identified in the initial phase. A third reviewer (AR) resolved 
any disagreement on the included articles. 
Types of Studies 
Randomised controlled trials (either parallel or crossover) with a treatment 
and follow up of at least two weeks were sought. Up-titration studies must 
have had blood pressure or safety data for at least the first two weeks before 
titration occurred. Studies were included only if there were efficacy or safety 
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data that were measured for at least one of the five major classes of blood 
pressure lowering medications: calcium channel blockers (CCBs), beta-
blockers (BBs), angiotensin receptor II antagonists (ARBs), angiotensin 
converting enzyme inhibitors (ACE-Is) and thiazide diuretics (TZs). All 
included medications were registered for use by the Food and Drug 
Administration (FDA) or European Medicines Advisory (EMA), and indicated 
for the treatment of hypertension. 
Studies were eligible for inclusion if participants were ≥ 18 years of age and 
written and published in English. No study was excluded on the basis of 
baseline blood pressure, presence or absence of disease or year performed. 
Studies were only considered if at least one arm was allocated quarter-dose 
therapy (with one or multiple agents) and at least one arm allocated placebo 
and/or standard dose monotherapy (in order to allow comparison with the 
2007 trial8). In this review, the standard dose was defined as the most 
reported usual maintenance dose recorded by the British National Formulary 
(BNF), Martindale and Monthly Index of Medical Specialties (MIMS), similar to 
the method of Law et al.7 The World Health Organisation Defined Daily Dose 
(WHO-DDD) was used as a tiebreaker if no consensus was found. If there 
was still no consensus between the selected pharmacopoeias, the most 
reported dose was judged as the standard dose (Table 1). However, there 
were two exceptions. A quarter dose of hydrochlorothiazide (HCTZ) of 6 mg 
and 5 mg were utilized for the studies by Jounela et al10 and Pool et al11 
because there was no 6.25 mg arm. 
Efficacy was assessed using the mean absolute difference between the 
intervention and control deltas (mean changes in systolic blood pressure 
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(SBP) and diastolic blood pressure (DBP) from baseline to end-of-study). 
Safety was defined as adverse events (all and side effect related, as defined 
by each trial) at follow up, and change in biochemical data (potassium and 
uric acid) from baseline to follow up.  
Data extraction and risk of bias 
Two reviewers (AB, MC) independently extracted data using a standard 
extraction form. The variables extracted included study design, sample size, 
mean age, percentage female, randomisation, blinding, intervention, dose(s), 
follow up, % lost to follow-up and study outcomes. In studies where numerical 
blood pressure changes were not presented (n=5), a visual estimate was 
made based on the figures provided. Both reviewers independently estimated 
the difference, with the average of the two being used.  
The two reviewers (AB, MC) also independently assessed the risk of bias in 
each trial based on the Cochrane Collaboration’s risk of bias tool12 (please 
see http://hyper.ahajournals.org, Figure S8). This estimates the risk based on 
sequence generation, allocation concealment, selective outcome reporting, 
potential threats to validity, blinding of participants, personnel and outcome 
assessors, and incomplete data. The risk of bias in each included trial was 
reported as low, unclear or high. A third reviewer (AR) resolved any 
differences.  
Data analysis 
One reviewer (AB) entered the data into Microsoft Excel and then into the 
Comprehensive Meta-analysis Software.13 A second reviewer (H-M D) 
checked the data for accuracy with a third reviewer (AR) resolving any 
disagreements. The data were analysed according to intention-to-treat when 
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possible.  Binary outcomes were analysed using the Mantel-Haenszel 
approach and summarised as risk ratios with 95% confidence intervals. 
Continuous outcomes were summarised as difference in means with 95% 
confidence intervals. Individual trial results were pooled using fixed-effect 
meta-analysis with inverse variance weighting. Heterogeneity was quantified 
by Q test, I2 and tau statistics 14, 15 (please see http://hyper.ahajournals.org, 
Table S2). Publication bias was assessed and reported using a funnel plot 
(please see http://hyper.ahajournals.org, Figure S6). 
Given the role of baseline blood pressure in determining the extent of blood 
pressure reduction from blood pressure lowering drugs,16 and since there was 
heterogeneity across trials in mean baseline levels, blood pressure was 
standardised to that expected from a baseline of 150/95 mmHg. This involved 
a 0.1 mmHg reduction in a given study’s SBP change score for each mmHg 
baseline SBP over 150 mmHg, and a 0.1 mmHg increase for each mmHg 
baseline SBP below 150 mmHg. Similarly, 0.11 mmHg was subtracted or 
added for each mmHg DBP above or below 95 mmHg.16 If no baseline blood 
pressure was reported for a given trial, then for that comparison the mean of 
the included trials was used. 
In order to analyse all randomised comparisons of quarter dose therapy vs. 
placebo and vs. standard dose monotherapy, some participants contributed to 
more than one analysis and not all comparisons within multi-arm trials were 
included. For example, Frishman et al17 conducted a 4x3 factorial dose 
response trial of two agents, with 12 cells labeled A-L in the table below: 
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  Thiazide dose 
 
 











0 A B C 
¼ D E F 
1 G H I 
4x J K L 
 
These cells contributed to the different analyses in the following way: 
Comparison Cells included in comparison(s) 
¼ vs. placebo D vs. A, B vs. A  
¼ vs. standard dose B vs. ½(C+G), D vs. ½(C+G) 
 Dual ¼ vs. placebo E vs. A 
Dual ¼ vs. standard 
dose 
E vs. C, E vs. G 
 
Variability data were absent in 12 trials, in which cases the standard deviation 
(SD) was imputed as a pooled SD derived from other trials with similar study 
arms.18 Although not ideal, this approach has been used in such occasions as 
outlined by the Cochrane Handbook of Systematic Reviews of Interventions.19 
All biochemical data reported had missing variability data and thus a common 
SD was used, derived for potassium from the Antihypertensive and Lipid 
Lowering Treatment to Prevent Heart Attack (ALLHAT),20 and for uric acid 
from the review by Weidmann et al.21 Meta-regression was used to undertake 
subgroup analysis of the effect that age and treatment period (>6 weeks) had 
on efficacy. Also, three sensitivity analyses were undertaken, to compare 
fixed-effect vs. random effects models, standardised vs. non-standardised 
blood pressure differences, and the impact of imputation for studies with 
missing variability data. 
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RESULTS 
Search results 
The initial search identified 1,730 studies, with 1,554 screened following 
exclusion of duplicate citations (figure 1). 58 studies with extractable data met 
the inclusion criteria, and 16 studies were excluded after full text evaluation. A 
total of 42 studies were included in the meta-analysis (please see 
http://hyper.ahajournals.org, supplemental material). 
Study characteristics 
Table S1 of the online supplement details the characteristics of included 
studies (please see http://hyper.ahajournals.org). On average the trials were 
published 17 years ago, and 85% of trials had eligibility criteria based solely 
on DBP. Of the 42 studies, 38 reported quarter-dose monotherapy, seven 
reported dual quarter-dose combination therapy and two reported quadruple 
quarter-dose therapy compared to either placebo or each component at a 
standard dose. Follow-up ranged from 4 to 12 weeks, averaging 7 weeks. 
Most studies were dose response trials testing 3 to 4 doses of one agent vs. 
placebo. Fourteen trials (please see http://hyper.ahajournals.org. Supplemental 
material: included trials 8, 10, 12-13, 15, 17-18, 20, 21, 22, 24, 34-35, 37) 
were factorial dose response trials, testing several doses of two agents. Only 
one out of the 42 studies did not have at least one arm containing standard 
dose monotherapy, and all but two included a placebo control arm. Overall, 
there were 20,284 participants with a mean age of 54 years, 61% were male 
and mean baseline blood pressure was 154/101 mmHg.  
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Efficacy 
Quarter-dose therapy vs. placebo 
The efficacy in blood pressure lowering of single quarter-dose therapy vs. 
placebo was assessed in 4,721 participants in 36 trials (Figure 2). Overall, 
placebo-corrected single quarter-dose therapy reduced blood pressure by -4.7 
(95%CI -5.4, -3.9)/ -2.4 (-2.8, -1.9) mmHg. There was broad consistency in 
treatment effect across the five major treatment classes (I2 SBP: 3, DBP: 0), 
and each was separately significant except for CCBs.  
Six trials measured the efficacy of dual quarter-dose therapy compared to 
placebo (Figure 2). All but one trial used a TZ diuretic in the dual quarter dose 
combination. In the 312 participants assessed, the effect of the dual quarter-
dose combination was an overall blood pressure drop of -6.7 (-8.6, -4.8)/ -4.4 
(-5.5, -3.3) mmHg. There was some evidence of heterogeneity present across 
the different dual combinations (I2 SBP: 18, DBP: 37). No studies measured 
triple quarter-dose therapy vs. placebo. One study (please see 
http://hyper.ahajournals.org. Included trial 40) measured efficacy of quadruple 
quarter-dose therapy vs. placebo and showed an office blood pressure 
reduction of -22.4 (-28.3, -16.5)/ -13.1 (-17.3, -8.8) (Figure 2). This was the 
only trial to report effects on 24-hour blood pressure profile, with reductions in 
24 hour, day-time and night-time BP of -18.7/-14.2, -22.3/-15.3 mmHg and -
10.4/-12.5 mmHg, respectively. 
Quarter-dose therapy vs. standard dose monotherapy 
Figure 3 illustrates the comparisons of single, dual and quadruple quarter-
dose therapy compared to standard dose monotherapy on blood pressure 
reductions. Single quarter-dose therapy was less efficacious than standard 
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dose monotherapy by 3.7 (3.0, 4.5) /2.6 mmHg (2.2, 3.1) (I2 SBP: 24.3, DBP: 
10.2). Dual quarter-dose therapy showed an equivalent blood pressure 
lowering effect compared to standard dose monotherapy. Only one study8 
assessed blood pressure lowering with quadruple quarter-dose therapy vs. 
standard dose monotherapy, and showed a substantially greater blood 
pressure reduction in the quarter dose group of -13.1 (-20.1, -6.1) / -7.9 (-
12.1, -3.7) mmHg. 
Safety and tolerability 
Adverse events 
Fifteen studies provided data on adverse events. Overall, compared to 
placebo, no significant difference in the risk of adverse events in the 14 single 
quarter-dose comparisons [RR 1.0 (0.91, 1.2), I2: 20.8]. This was also 
observed in 6 dual quarter-dose comparisons [0.93 (0.29, 2.9)] and in a 
solitary quadruple [2.0 (0.2, 20.2)] quarter-dose placebo comparison (Figure 
4). Moreover, no individual medication class was associated with a greater 
risk of adverse events compared to placebo. Both single and dual quarter 
dose therapy produced significantly fewer adverse events than standard dose 
monotherapy (Figure 4). In terms of tolerability of quadruple quarter dose 
therapy, in the 2007 trial compared to standard dose therapy the only 
information available was that “therapy was well tolerated by all of the 
participants, and, in particular, there was no case of hypotension.”(personal 
communication, J Feely). In the 2017 trial, no patient withdrew because of 
side effects.9 However, in each trial treatment was for only 4 weeks and a total 
of 40 patients received quadruple quarter dose therapy. 
April 28, 2017 – Page 13 
Biochemical adverse effects 
Table 2 compares the mean difference from baseline to follow up in 
biochemical measures, for placebo, single quarter-dose, dual quarter-dose 
and standard dose therapy. Overall, data on potassium concentrations were 
reported in 10 studies; of these, 8 were amenable to pooling. Compared to 
placebo, none of the single (n=5), dual (n=3) or quadruple (n=1) quarter-dose 
therapy comparisons showed a significant difference in potassium 
concentration. Treatment with TZ standard dose monotherapy (n=4) resulted 
in a significantly greater reduction in potassium concentration compared to 
single quarter-dose TZ, dual ¼ BB + ¼ TZ and dual ¼ ACE-I + ¼ TZ. Similar 
trends were seen in two trials reporting the proportion of patients below a 
certain potassium level (<3.5 mmol/L)22 or the number of participants who 
developed a >0.05 mmol change in potassium concentration.23 
Three studies reported data on uric acid concentrations in a format that 
allowed the data to be pooled. Compared to placebo, no significant 
differences were observed for single or dual quarter-dose treatment arms, 
however quadruple quarter-dose therapy did result in a small increase 
compared to placebo (0.03, 95% CI 0.001 – 0.04 mmol/L; p=0.003). Standard 
dose TZ resulted in greater uric acid concentration vs. single quarter-dose TZ, 
vs. dual ¼ ARB + ¼ TZ and vs. dual ¼ BB + ¼ TZ. These findings are 
comparable to one trial which only reported percentage change from 
baseline.24 There was a also a small difference in creatinine compared with 
quadruple quarter dose therapy compared to placebo (4.4, 95% CI 0.9 – 7.8 
mmol/L; p=0.02) but no patient had more than a 12% increase.9  
Effects on heart rate were generally not reported but were available for both 
quadruple quarter dose combinations: Chow et al9, 2017 reported a reduction 
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of 6·5 beats per minute (95% CI 2·3–10·6) compared to placebo and Mahmud 
and Feely8 reported a reduction from baseline of 6 SD 3 beats per minute.  
Quality of evidence 
The Trim and Fill approach did not suggest evidence of publication bias 
(please see http://hyper.ahajournals.org, Figure S6). The risk of bias was 
assessed in all 42 studies (please see http://hyper.ahajournals.org, Figure S8). 
Overall, eight studies described the method of sequence generation; seven 
described the method of concealment and 28 described and dealt with 
missing data. In the absence of detailed study protocols, it was not possible to 
assess whether outcomes were selective. Likewise, other potential threats to 
validity could not be assessed. Blinding of participants and personnel was 
undertaken in some capacity for 41 trials (40 of which were double-blinded, 
one single-blinded and one open-label). 
Subgroup analyses 
Subgroup analyses undertaken using meta-regression did not suggest any 
significant correlation between DBP lowering and age (p=0.38) or >6 week 
treatment (p=0.18) (please see http://hyper.ahajournals.org, Figure S7). 
Sensitivity analyses 
The mean blood pressure reduction for a single quarter dose vs. placebo was 
essentially the same using the random effects model [-4.7 (-5.4, -3.9)/-2.3 (-
2.8, -1.9) mmHg], compared to the fixed-effect model [-4.7 (-5.4, -3.9)/ -2.4 (-
2.8, -1.9)] mmHg]. Exclusion of studies with missing data on variability also 
did not substantially affect this estimate [-5.0 (-5.7, -4.2)/-2.4 (-2.9, -1.8) 
mmHg]. Finally, pooling of non-standardised changes in blood pressure, 
rather than changes standardised to a baseline blood pressure of 150/95 
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mmHg provided an overall estimate of -5.0 (-5.8, -4.3)/ -2.9 (-3.4, -2.3) mmHg 
for quarter dose therapy vs. placebo.  
DISCUSSION 
This review is the first to compare quarter-dose therapy to both standard dose 
and placebo, and indicates a potential clinical advantage in terms of reducing 
side effects and, with the use of quadruple combinations, increasing efficacy. 
Single quarter dose therapy reduced blood pressure by about -4.7/ -2.4 
mmHg compared to placebo (about half as much as standard dose 
monotherapy), with no apparent side effects. Dual quarter-dose therapy had 
about the same efficacy as standard dose monotherapy, with fewer side 
effects. The data on quadruple quarter-dose therapy was limited to two small 
trials that indicated these combinations are significantly more efficacious than 
placebo and standard dose monotherapy. A clear dose response in efficacy 
was seen between single, double and quadruple quarter-dose therapy.  
Strengths and weaknesses of the study 
This review has several strengths. It was conducted in line with recommended 
systematic review methodology and included a relatively large number of 
studies, doubling the number of trials of quarter-dose therapy included in a 
previous systematic review.9 Several studies were identified in regulatory 
submissions that had not been published in the medical literature. The large 
number of trials allowed precise estimates of treatment effects, at least for 
single and dual combinations, and assessment of consistency of results 
across major drug classes. The review also has some limitations. We did not 
review non-English language trials. No individual patient data were used and 
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data were not checked with original trialists since most trials were completed 
more than 17 years ago. There were some missing data, particularly on 
variability, but sensitivity analyses did suggest the findings were reasonably 
robust. Only one trial assessed effects on 24 hour BP profile, and it remains 
unknown whether better night-time BP reduction can be achieved with 
different components. Lastly, defining standard dose involved some 
assumptions, but to minimise their impact the authors used data from four 
pharmacopoeias. 
Context of other evidence 
Law et al undertook the most relevant previous review in 2003, which 
assessed placebo-controlled trials of blood pressure lowering drugs available 
at that time.9 The principal aim of that review was to quantify effects of 
standard doses of blood pressure lowering agents and dose response. 
Analysis of low dose therapy was largely restricted to half dosages, indicating 
half dose blood pressure treatment was approximately 80% as efficacious as 
standard dose, and that side effects generally rose steeply with dose. In terms 
of results for quarter dose therapy, there were limited data on efficacy and no 
analyses on side effects from the 19 studies quantifying single quarter dose 
effects in the Law 2003 review. The present review included a further 23 trials 
of quarter dose therapy. As with the current review, Law et al did not find any 
clear evidence that one drug class was more effective than any other. 
However, as with other systematic reviews of dose response within treatment 
classes,25 Law et al also noted that there is considerable variability in potency 
per mg, and so the choice of standard dose is relevant to such comparisons. 
In the context of other low-dose combination therapy trials, the most relevant 
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compared triple half-dose therapy (amlodipine 2.5 mg, losartan 25 mg, 
hydrochlorothiazide 12.5 mg) with placebo and also observed a large blood 
pressure reduction, of -17.9/ -9.8 mmHg.26  
Perspectives 
This review suggests a potentially broader clinical role for low-dose blood 
pressure lowering drugs.  Use of dual quarter dose blood pressure lowering 
therapy may be preferable to standard dose monotherapy, given comparable 
blood pressure reduction with better tolerability. Alternatively, addition of a 
single quarter-dose agent to existing therapy is likely to confer an extra 3-4 
mmHg systolic blood pressure reduction without additional side effects and 
thus could be preferable to doubling the dose of the existing agent, which on 
average confers only about a 1-2mmHg extra systolic blood pressure 
reduction at the expense of increased side effects.7, 27 Currently there are a 
few low-dose combinations available to clinicians: for example a bisoprolol-
hydrochlorothiazide combination is on the market in the USA (Ziac), with a 
dual quarter dose version indicated for initial treatment of hypertension; a 
perindopril-indapamide combination is available that includes half dose and 
quarter dose, supported by clinical trial data showing improved rates of 
adverse event-free blood pressure control compared to sequential 
monotherapy or stepped care.28 Quarter doses are available for many beta-
blockers and are obtainable for other classes from halving existing half-doses.  
However, for many patients more blood pressure reduction than that given by 
standard dose monotherapy or dual quarter dose therapy is needed.29 This 
review suggests considerably more research is required, to examine the 
potential of triple or quadruple quarter- dose combinations to determine 
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whether they could provide substantial blood pressure lowering with little or no 
drug-specific side effects i.e. more or less “pure” blood pressure lowering. 
Future trials should explore this hypothesis, testing quarter dose combinations 
as initial therapy and also for those uncontrolled on monotherapy who need 
additional blood pressure reduction; and for particular patient groups of 
interest, such as the elderly or those with impaired renal function. Further 
information on tolerability of such combinations is critical, given the near 
absence of data in this regard. Relevant clinical trials should also assess 
patient acceptability and the potential for low dose combination pills to 
improve long-term adherence.    
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Novelty and Significance  
What Is New? 
There are few data on the efficacy or tolerability of ultra-low dose blood 
pressure combinations.  
What Is Relevant?  
Dual quarter-dose therapy is as effective as standard dose monotherapy, with 
fewer side effects.  
Quadruple quarter-dose therapy appears to be around twice as efficacious as 
standard dose monotherapy, but there are few data on side effects 
 
Summary 
Quarter dose combinations could provide improvements in efficacy and 
tolerability of blood pressure lowering therapy 
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FIGURE LEGENDS 
Figure 1 – Study flow includes the number of articles identified, eligible and 
included 
Figure 2 - DBP- Diastolic Blood Pressure, SBP – Systolic Blood Pressure, CI- 
Confidence Interval, ACEI – Angiotensin Converting Enzyme Inhibitor, ARB – 
Angiotensin Receptor Blocker, BB- Beta-blocker, CCB- Calcium Channel 
Blocker, TZ- Thiazide Diuretic. Data presented as difference in means (lower 
confidence limit, upper confidence limit). Heterogeneity (Q value, p-value, I2 
statistic) observed for single quarter vs. placebo, DBP: 32, 0.75, 0. SBP: 39, 
0.37, 3.0 and observed for dual quarter vs. placebo, DBP: 8, 0.16, 37. SBP: 
3.7, 0.36, 18.2. Trial and participant numbers represent single quarter dose 
vs. placebo DBP analysis. Quarter dose vs. placebo SBP analysis trials=34, 
participants=4,573. Mean difference (mmHg) = 1/4 dose(s) – placebo 
Figure 3 - DBP- diastolic Blood Pressure, SBP – Systolic Blood Pressure, CI- 
Confidence Interval. Data presented as difference in means (lower confidence 
limit, upper confidence limit). Heterogeneity (Q value, p-value, I2 statistic) 
observed for single quarter dose vs. standard dose, DBP: 37, 0.5, 0. SBP: 46, 
0.1, 22. Observed for dual quarter dose vs. standard dose, DBP: 13, 0.04, 55. 
SBP: 4, 0.69, 0) Trial and participant numbers represent single quarter dose 
vs. standard dose DBP analysis. Quarter dose vs. standard dose SBP 
analysis trials=35, participants=5,146. Mean difference (mmHg) = 1/4 dose(s) 
– standard dose 
Figure 4 -  CI- Confidence Interval, ACEI – Angiotensin Converting Enzyme 
Inhibitor, ARB – Angiotensin Receptor Blocker, BB- Beta-blocker, CCB- 
Calcium Channel Blocker. Risk ratio presented as risk ratio (lower confidence 
interval, upper confidence interval). Heterogeneity (Q value, p-value, I2 
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statistic) observed for single quarter dose vs. placebo: 6, 0.8, 0 observed for 
single quarter vs. standard dose: 17, 0.11, 35 observed for dual quarter vs. 
standard dose: 0.4, 0.52, 0
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Table 1. Standard dosing table for included trial medications 
Medication WHO Defined Daily Dose* BNF dose range 
Martindale dose 
range MIMS dose range 
Standard dose 
selected for this 
review 
Beta-blocker      
atenolol 75mg 25-50 mg 50-100 mg 50-100 mg 50 mg 
metoprolol 150 mg 100-200 mg 100-200 mg 100-200 mg 100 mg 
bisoprolol 10 mg 10 mg 10 mg 10 mg 10 mg 
carvedilol 37.5 mg 25 mg 25 mg 25-50 mg 25 mg 
nebivolol 5 mg 5 mg 5- 40 mg 5 mg 5 mg 
penbutolol 40 mg - 20-40 mg - 40 mg 
CCB         
amlodipine 5 mg 5 - 10 mg  5 - 10 mg 2.5 - 10 mg 5 mg 
lercanidipine 10 mg 10-20 mg 10-20 mg 10 mg 10 mg 
nitrendipine 20 mg - 20 mg - 20 mg 
verapamil 240 mg 240- 480 mg 240 mg 240 mg 240 mg 
ACE Inhibitor         
captopril 50 mg 25-150 mg 100-150 mg 50-100 mg 100 mg 
benazepril 7.5 mg - 20-40 mg - 20 mg 
fosinopril 15 mg 10-40 mg 10-40 mg 10-40 mg 10 mg 
lisinopril 10 mg 20 mg 20 mg 10-20 mg 20 mg 
quinapril 15 mg 20-40 mg 20-40 mg 10-40 mg 20 mg 
trandolapril  2 mg 1-2 mg 1 - 2 mg 1- 2 mg 2 mg 
enalapril 10 mg 20 mg 10-20 mg 10-40 mg 20 mg 
ARB         
valsartan 80 mg 80 mg 80-160 mg 80 mg 80 mg 
irbesartan 150 mg 150 -300 mg 150 mg 150 mg 150 mg 
candesartan 8 mg 8 mg 8 mg 8-16 mg 8 mg 
April 28, 2017 – Page 31 
telmisartan 40 mg 40 mg 20-80 mg 40 mg 40 mg 
olmesartan 20 mg 10-20 mg 20 mg 20 mg 20 mg 
azilsartan             - 40 mg 40 mg 
 
40 mg 
TZ      
hydrochlorothiazide 25 mg - 25-50 mg - 25 mg 
bendroflumethazide 2.5 mg 2.5 mg 2.5 mg - 2.5 mg 
Standard dose was defined as the most reported usual maintenance dose recorded by the British National Formulary (BNF), Martindale and Monthly Index of Medical Specialties (MIMS). If no consensus was found, the World Health 
Organisation Defined Daily Dose (WHO-DDD) was used as a tiebreaker. If there was still no consensus between the selected pharmacopoeias, the lowest, most reported dose was judged as the standard dose. CCB - Calcium Channel 
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Table 2. Change in biochemical measures from baseline to follow up with single and dual 
quarter-dose therapy, compared with placebo and standard dose monotherapy  
 
CI- Confidence Interval, ACEI – Angiotensin Converting Enzyme Inhibitor, ARB – Angiotensin Receptor Blocker, BB- Beta-blocker, CCB- Calcium 
Channel Blocker., TZ – Thiazide diuretic, 1- standard dose, ¼ - quarter dose. Presented as mean difference (lower confidence interval, upper 
confidence interval). * represents P-value<0.05. ** signifies a trial that did not compare a dual combination with its component quarter doses. 
Mean difference = 1/4 dose(s) – (placebo or standard dose). Potassium: TZ vs. placebo 0.522, 0.91, 0. TZ vs. 1 dose 0.17, 0.98, 0; Uric acid: TZ 







Quarter-dose(s) Comparison group Trials Patients Mean difference (95%CI) P-value 
Potassium (mmol/L) 
¼ ACEI Placebo 1 88 0.14 (-0.15, 0.43) 0.35 Standard dose ACEI 85 0.01 (-0.29, 0.31) 0.95 
¼ BB Placebo 1 115 0.21 (-0.05, 0.47) 0.11 Standard dose BB 121 0.10 (-0.15, 0.35) 0.43 
¼ TZ Placebo  4 
 
294 -0.02 (-0.19, 0.16) 0.85 
Standard dose TZ 227 0.27 (0.08, 0.45) 0.01* 
¼ ACEI + ¼ TZ 
Placebo 
1 
83 0.03 (-0.27, 0.33) 0.85 
Standard dose ACEI 88 -0.22 (-0.51, 0.07) 0.14 
Standard dose TZ 85 0.36 (0.06, 0.66) 0.02* 
¼ ARB + ¼ TZ Placebo 1 77 -0.05 (-0.36, 0.26) 0.75 Standard dose TZ 75 0.22 (-0.1, 0.54) 0.17 
¼ BB + ¼ TZ 
Placebo 
1 
84 0.07 (-0.25, 0.39) 0.67 
Standard dose BB 90 -0.04 (-0.35, 0.27) 0.80 
Standard dose TZ 67 0.39 (0.05, 0.73) 0.02* 
**¼ BB + ¼ TZ Standard dose CCB 1 160 0.2 (-0.02, 0.42) 0.07 
¼ BB + ¼ TZ + ¼ 
ARB + ¼ CCB Placebo 1 19 0.1 (-0.1, 0.2) 0.90 





115 1.0 (-24.7, 26.7) 0.94 
Standard dose BB 121 -12.0 (-37.1, 13.1) 0.35 
¼ TZ Placebo  3 
 
200 9.4 (-10.8, 29.6) 0.36 
Standard dose TZ 182 -35.9 (-56.5, -15.2) 0.001* 
¼ ARB + ¼ TZ Placebo 1 77 11.7 (-19.7, 43.1) 0.47 Standard dose TZ 75 -39.8 (-71.5, -8,1) 0.01* 
¼ BB + ¼ TZ 
Placebo 
1 
84 -2.0 (-33.9, 29.9) 0.90 
Standard dose BB 90 -15.0 (-46.2, 16.2) 0.35 
Standard dose TZ 67 -48.0 (-82.0, -14.0) 0.01* 
**¼ BB + ¼ TZ Standard dose CCB 1 160 29.0 (7.3, 50.7) 0.01* 
¼ ARB + ¼ BB + 
¼ CCB + ¼ TZ Placebo 1 19 100.0 (5.0, 195.0) 0.03* 
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Figure 1. PRISMA Flow Diagram 
 
Figure 2: Efficacy of single, dual and quadruple quarter-dose therapy on blood 
pressure lowering, compared to placebo 
 
Figure 3. Efficacy in blood pressure lowering of number of quarter-dose agents 
compared to standard dose monotherapy 
 
Figure 4. Risk of adverse events with increasing number of quarter-dose agents 
compared to placebo and standard dose monotherapy 
